Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1056
- Registration Number
- NCT01345734
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1663
- Registration Number
- NCT01336023
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom
Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01319240
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus
- Conditions
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT01299012
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 653
- Registration Number
- NCT01296412
Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 254
- Registration Number
- NCT01288326
- Locations
- 🇧🇪
Novo Nordisk Investigational Site, Brussels, Belgium
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3731
- Registration Number
- NCT01272219
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 846
- Registration Number
- NCT01272232
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
LIraglutide and Beta-cell RepAir (LIBRA) Study
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 63
- Registration Number
- NCT01270789
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 52
- Registration Number
- NCT01237119
- Locations
- 🇬🇧
NIHR BRU Centre for liver research, Queens Elizabeth University Hospital Birmingham, Birmingham, West Midlands, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.